June 4, 2015

Dr. Stephen Ostroff
Commissioner
U.S. Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993

Dear Commissioner Ostroff:

We write to you to request that the Food and Drug Administration (FDA) invoke its authority under section 505(o)(4) of the Food, Drug, and Cosmetic Act (the FD&C Act) to require manufacturers of Immediate Release (IR) opioid analgesics to make labeling changes to more effectively communicate the serious risks of abuse, neonatal abstinence syndrome (NAS), addiction, overdose, and death associated with the use of opioid analgesics.

Given the national public health crisis of prescription drug overdoses, an issue that has been a subject of extensive examination by the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations, we believe this common sense approach would equip patients and prescribers with information necessary to make informed decisions regarding the risks of opioid analgesics.

The Centers for Disease Control and Prevention (CDC) has declared prescription drug abuse in the United States an epidemic and has found drug overdose to be the leading cause of injury death in the United States.\(^1\) Between 2000 and 2010, there was a fourfold increase in the use of prescribed opioids for the treatment of pain.\(^2\) This increase in opioid prescriptions has been mirrored by a fourfold increase in opioid-related overdose deaths: between 1999 and 2010,


the death rate from prescription opioids more than quadrupled. In addition to the tragic losses of life and the impact on families and communities, the opioid abuse epidemic has had significant costs to our healthcare system. In 2010, drug overdoses from prescription opioids were involved in an estimated 80,095 hospital visits costing $1.3 billion.

The incidence of neonatal abstinence syndrome (NAS) has also skyrocketed. NAS is associated with preterm births, low birthweight, and complications such as respiratory distress and seizures. According to a recent study in the New England Journal of Medicine, from 2004 through 2013, the incidence of NAS quadrupled. In 2012, aggregate hospital charges for NAS were $1.5 billion, with 81% attributed to state Medicaid programs.

In 2013, in response to a citizen petition submitted by Physicians for Responsible Opioid Prescribing (PROP), the FDA adopted labeling changes to more effectively communicate to prescribers and patients the serious risks associated with opioid analgesics. The FDA required manufacturers to adopt the most restrictive language that can be found in drug labeling, a “black box” warning about their potential for abuse, the risk of fatal overdose, and a warning that maternal use of these products during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening. For example, the label for the recently approved ZOHYDRO ER extended-release capsules contains the following black box warning, in bold print:

“WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTION WITH ALCOHOL; and CYTOCHROME P450 3A4 INTERACTION.”

---


4 Michael A. Yokell et. al., Presentation of Prescription and Nonprescription Opioid Overdoses to US Emergency Departments, JAMA Internal Medicine (Oct. 27, 2014).


8 Letter from Dr. Janet Woodcock, Director, Center for Drug Evaluation and Research, Food and Drug Administration, to Dr. Andrew Kolodny, President, Physicians for Responsible Opioid Prescribing, Re: Docket No. FDA-2012-P-0818 (Sept. 10 2013).

9 Id.
This lead sentence is followed by additional detail regarding these risks, and recommendations for prescribers, including a recommendation that prescribers assess each patient’s risk for addiction, abuse, and misuse before prescribing and monitoring patients regularly for development of these behaviors and conditions.\textsuperscript{10}

However, FDA chose to apply this black box warning only to Extended Release and Long-Acting (ER/LA) opioid analgesics. The FDA letter responding to the PROP petition noted that ER/LA opioid analgesics have disproportionate safety concerns compared to IR opioids and opioid/non-opioid combination products.\textsuperscript{11} The FDA cited the fact that ER/LA opioids may contain higher doses of opioids compared to IR products, and are often used in a chronic pain setting, as justification for drawing this distinction.\textsuperscript{12}

However, as the agency also acknowledged, much of the literature FDA reviewed that provided the basis for the labeling change assessed opioid use from all opioid sources, and did not separate data according to opioid formulation.\textsuperscript{13} Indeed, the body of evidence regarding the association between opioid prescribing and addiction, overdoses, death, and neonatal abstinence syndrome do not favorably distinguish the IR formulations from the ER/LA formulations in terms of health outcomes.\textsuperscript{14} A recent systematic review by the Agency for Health Research and Quality (AHRQ) did not identify a single study that found statistically significant differences between short versus long-acting opioids on the risks of overdose, addiction, abuse, or misuse in patients with chronic pain.\textsuperscript{15}

\textsuperscript{10} \textit{Highlights of Prescribing Information, ZOHYDRO ER (hydrocodone bitartrate) extended-release capsules, for oral use, C11} (available at www.accessdata.fda.gov/drugsatfda_docs/label/2015/202880Orig1s003lbl.pdf) (accessed May 12, 2015).

\textsuperscript{11} Letter from Janet Woodcock, Director, Center for Drug Evaluation and Research, Food and Drug Administration, to Dr. Andrew Kolodny, President, Physicians for Responsible Opioid Prescribing, Re: Docket No. FDA-2012-P-0818 (Sept. 2013).

\textsuperscript{12} \textit{Id}.

\textsuperscript{13} \textit{Id}.


\textsuperscript{15} Agency for Healthcare Research and Quality, \textit{Evidence Report/Technology Assessment: The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain} (Sept.
Additionally, IR opioid analgesics are widely prescribed and used in the United States. According to one estimate, IR opioids represent 91% of all outpatient opioids prescribed in 2009, with ER opioids comprising 9% of prescriptions.\textsuperscript{16} For example, hydrocodone acetaminophen was the most widely prescribed drug to Medicare beneficiaries in 2013.\textsuperscript{17} In 2011, 131 million prescriptions for combination hydrocodone-containing analgesics (products containing hydrocodone as well as non-opiate drugs such as ibuprofen and acetaminophen) were dispensed in the United States, representing over 47 million patients.\textsuperscript{18}

The widespread use and resulting large-scale public health impact of IR hydrocodone combination products was a factor that affected the Department of Health and Human Services’ (HHS) recommendation that these products be rescheduled from Schedule III to Schedule II under the Controlled Substances Act. The Department recommended this rescheduling of hydrocodone products due to their “high potential for abuse” and the fact that their abuse “may lead to severe psychological or physical dependence.” While acknowledging that hydrocodone combination products have a lower risk per exposure than products containing oxycodone, HHS observed that the huge volume of hydrocodone prescriptions in the U.S. results in a serious public health impact:

[H]ydrocodone is unlike any other opioid regarding the unprecedented number of hydrocodone prescriptions in the U.S. each year. It is this characteristic of the use of hydrocodone combination products that drives the potential for abuse of these products and sets hydrocodone apart from any other opioids in terms of risks for abuse.\textsuperscript{19}

Additionally, a recent study of the Tennessee Medicaid program in *Pediatrics* found that 28% of women in the program were prescribed opioid pain relievers during pregnancy. Of the infants that were born with NAS, 65% had mothers that had received legal prescriptions for opioid pain relievers. Nearly all of the women who were legally prescribed opioids (96%) were


\textsuperscript{17} *Generic Vicodin Was a Top Medicare Drug in 2013, Data Shows*, Wall Street Journal (May 4, 2015).

\textsuperscript{18} Letter from Howard K. Koh, Assistant Secretary for Health, Department of Health and Human Services to Michele M. Leonhart, Administrator, Drug Enforcement Administration, U.S. Department of Justice Re: Basis for the Recommendation to Place Hydrocodone Combination Products in Schedule II of the Controlled Substances Act (Dec. 16, 2013).

\textsuperscript{19} *Id.*
Commissioner Ostroff  
June 4, 2015  
Page 5  
prescribed IR medications—only 0.6% were prescribed long-acting preparations.\(^20\) It is critical  
that pregnant women and their physicians have access to clear, concise information about the  
risks of NAS when considering whether to prescribe opioid therapies during pregnancy, and we  
are concerned that the current labeling for IR opioids does not meet this threshold.  

Given the established risk of addiction, abuse and overdose from all opioid analgesics, as  
well as the emerging public health threat of NAS, we believe that the FDA should ensure that all  
IR opioid formulations bear the same black box warning as the ER/LA formulations. We believe  
that this information is crucial to patients and prescribers, and we ask that you work  
expediously to address this issue. Please provide a response in writing by June 29, 2015, to this  
letter, including whether FDA plans to require the labeling change to the IR opioid formulations  
as we request, why or why not, and an approximate timeline for any such planned labeling  
change requirement.  

Additionally, FDA’s response to the PROP petition describes a mandatory process for  
manufacturers of ER/LA opioids to conduct post-marketing reviews to assess the safety of long  
term use of opioids. The response indicates that sponsors are required to submit final study  
protocols to FDA by August 2014. Please provide copies of these final protocols, any finalized  
reports, and an update on the status of these studies, which are scheduled to be completed as  
early as August 2015. Please provide the requested information by no later than June 29, 2015.  

Thank you for considering our views.  

Sincerely,  

FRANK PALLONE, JR.  
Member of Congress  

BOBBY L. RUSH  
Member of Congress  

DIANA DEGETTE  
Member of Congress  

GENE GREEN  
Member of Congress  

ELIOT L. ENGEL  
Member of Congress  

LOIS CAPPS  
Member of Congress  

\(^{20}\) Stephen W. Patrick et. al., *Prescription Opioid Epidemic and Infant Outcomes*,  